Galapagos (NASDAQ:GLPG) executives used the company’s first-quarter 2026 earnings call to highlight what Chief Executive ...

Advancing next-generation γδ T cell engager platform with initial animal data expected in 2026Reported glioblastoma (GBM) data showing ~97% ...

Cytospire Therapeutics has secured $83 million in Series A funding to progress its first-in-class pan-gamma delta T cell engagers into clinical trials for cancer. The approach aims to overcome safety ...

Trispecific antibodies are emerging as one of the most exciting drug classes in biopharma, building on the clinical success of bispecific antibodies to deliver even greater efficacy and precision. By ...

Net loss attributable to Xencor for the first quarter ended March 31, 2026 was $128.9 million, or $ (1.71) on a fully diluted per share basis, compared to net loss of $48.4 million, or $ (0.66) on a ...

In April 2026, Context received Human Research Ethics Committee (“HREC”) approval and Clinical Trial Notification (“CTN”) acknowledgement by the Australian Therapeutic Goods Administration (“TGA”) to ...

UCB has agreed to acquire Candid Therapeutics for up-to-$2.2 billion, in a deal designed to expand the buyer’s presence in ...

Republican Ron Hanks, a former state lawmaker and U.S. Air Force intelligence officer, told the Vail Daily in a recent email ...

Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a ...

The British biotechnology startup is making "pan-gamma delta” T cell engagers it says can address the limitations of similar, ...